Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial.
Paul Russell, Kathy Woodward, David Morris, Niyati Prasad, Rachael White, Denisa Wilkes, Martin Gosling, Henry Danahay
Published: 202510.1016/j.jcf.2025.11.015
Abstract
BACKGROUND: Inhibition of the epithelial sodium channel, ENaC, in the airways of people with cystic fibrosis, represents an approach to restore airway mucus hydration and clearance. ETD001 is a novel inhaled ENaC blocker that has been designed to pro…
Preview only. Read the full abstract at the source